Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

AAcurx Pharmaceuticals, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
A

Acurx Pharmaceuticals, Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • “Comparative In Vitro Killing Kinetics of Ibezapolstat and Comparator Antibiotics in Clostridioides difficile and Vancomycin-resistant Enterococcus Co-Cultures” dated September 2026, by Dr. Eugenie Bassères, Research Scientist, University of Houston College of Pharmacy (C. Difficile Symposium, Bled, Slovenia)
    Sep 26, 2026Acurx Pharmaceuticals, Inc. (ACXP) - Presentations
  • “Microbiome Restoration Potential of Ibezapolstat vs. Comparator Antibiotics in Patients with Multiply Recurrent Clostridioides difficile Infection (CDI)” dated July 10, 2026 by Bassères, Garey, et. al.
    Sep 26, 2026Acurx Pharmaceuticals, Inc. (ACXP) - Presentations
  • Leiden University Medical Center presents “A unique inhibitor conformation selectivity targets Gram + bacterial DNA replication” by Dr. Mia Urem, June 2026
    Sep 26, 2026Acurx Pharmaceuticals, Inc. (ACXP) - Presentations
  • ESCMID Poster Presentation “Preclinical Microbiome Evaluation of novel PolC-inhibitor compounds (Begum, et. al., April 2026)"
    Sep 26, 2026Acurx Pharmaceuticals, Inc. (ACXP) - Presentations
  • ID Week Presentation (October 2025) by Michael H. Silverman, MD, FACP and Kevin Garey, PharmD., MS
    Sep 26, 2026Acurx Pharmaceuticals, Inc. (ACXP) - Presentations
  • Corporate Presentation dated September 2025
    Sep 26, 2026Acurx Pharmaceuticals, Inc. (ACXP) - Presentations
  • Presentation, by Mia Urem, Ph.D., Leiden University Medical Center, “Machines on Genes 2025.”
    Sep 26, 2026Acurx Pharmaceuticals, Inc. (ACXP) - Presentations
  • Poster Presentation by Mia Urem, Ph.D., Leiden University Medical Center, “A unique inhibitor conformation selectively targets DNA polymerase PolC of Gram-positive priority pathogens”.
    Sep 26, 2026Acurx Pharmaceuticals, Inc. (ACXP) - Presentations
  • Presentation by Dr. Kevin Garey at the Peggy Lillis Foundation Inaugural CDI Scientific Symposium with Phase 2 Clinical Trial Update
    Sep 26, 2026Acurx Pharmaceuticals, Inc. (ACXP) - Presentations
  • Presentation at ICDS Conference, September 2024, Microbiome Results from the phase 2, randomized, double-blind study of ibezapolstat compared with vancomycin for the treatment of Clostridioides difficileinfection
    Sep 26, 2026Acurx Pharmaceuticals, Inc. (ACXP) - Presentations
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
$1.31Close · Oct 6, 2026